The aminoglycoside plazomicin has demonstrated noninferiority to meropenem, a broad-spectrum carbapenem antibiotic, for treating complicated urinary tract infection (UTI) and acute pyelonephritis, with the former yielding greater microbiologic eradication as reflected by lower incidences of recurrence and relapse, according to data from the phase III EPIC* trial.
Use of mirabegron in the treatment of men with overactive bladder (OAB) appears to effectively alleviate urgency and storage symptoms, but not reduce the frequency of micturition episodes, according to data from the MIRACLE study.
Radiotherapy in parallel with panitumumab use following induction chemotherapy and pelvic lymph node dissection appears to be well tolerated and is noninferior to the historical profile of concurrent radiotherapy and cisplatin, a study has shown.
Perioperative intake of an oral nutrition supplement may lead to a lower prevalence of sarcopaenia and fewer and less severe complications and readmissions among patients who undergo radical cystectomy, reports a study.
At the Eisai-sponsored tea symposium during the 27th Malaysian Urological Conference at Shangri-La Kuala Lumpur, Professor Osamu Yokoyama highlighted the advantages of silodosin (Urief®, Eisai Inc.) in relieving lower urinary tract symptoms associated with benign prostate hyperplasia.
Patients with renal cell carcinoma (RCC) who received the first-line combination of avelumab and axitinib had longer progression-free survival (PFS) compared with those who received sunitinib, particularly those with PD-L1–positive tumours, according to findings of the phase III JAVELIN Renal 101* trial.
A subgroup of patients with HBeAg-negative chronic hepatitis B virus (HBV) infection who ceased their long-term nucleotide analogue treatment maintained virological suppression, pointing to a group of patients who may be suitable for treatment cessation, according to a recent study.